Mbx Biosciences, INC Schedule 13G passive stakes

Deep Track Capital, LP, along with affiliated entities, has reported beneficial ownership of 3.64% of MBX Biosciences, Inc. common stock as of June 30, 2026.

Wellington Management Group LLP and its affiliates have reported a significant beneficial ownership stake of 10.5% in MBX Biosciences, as of June 30, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 11.2% of MBX Biosciences Inc.'s common stock as of June 30, 2026.

Paradigm BioCapital Advisors LP and associated entities have reported a 5.2% beneficial ownership stake in MBX Biosciences, Inc. as of June 16, 2026.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 6.2% of MBX Biosciences Inc. common stock as of March 31, 2026.

Wellington Management Group LLP and its affiliates have disclosed a 7.5% beneficial ownership stake in MBX Biosciences' Common Stock.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in MBX Biosciences Inc. common stock as of December 31, 2025.

P. Kent Hawryluk reported beneficial ownership of 4.3% of MBX Biosciences, Inc. common stock, totaling 1,995,759 shares.

Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. has filed an amended Schedule 13G, reporting a 4.5% passive ownership stake in MBX Biosciences' common stock.

Wellington Management Group and its affiliates reported a 10.8% beneficial ownership stake in MBX Biosciences, Inc., holding 4,823,336 common shares.

Deep Track Capital and affiliates disclose a 6.55% beneficial ownership stake in MBX Biosciences, Inc. common stock.

Wellington Management Group and its affiliates have disclosed a 6.78% beneficial ownership stake in MBX Biosciences, Inc. common stock.

Wellington Management Group LLP and its affiliated entities have filed an amended Schedule 13G, reporting a beneficial ownership of 7.89% of MBX Biosciences, Inc.'s common stock as of March 31, 2025.